Let me verify the case context and HMO Louisiana's corporate role.
HMO Louisiana, Inc. is a Louisiana health maintenance organization and a wholly owned subsidiary of Blue Cross and Blue Shield of Louisiana, whose legal name is Louisiana Health Service & Indemnity Company. The parent was founded in New Orleans in 1934 and is headquartered at 5525 Reitz Avenue, Baton Rouge. It is a nonprofit, policyholder-owned mutual company with no shareholders and no public ticker, and an independent licensee of the Blue Cross Blue Shield Association operating only in Louisiana. Public sources place the parent at roughly 2,100–2,500 employees with about 1.8 million members; HMO Louisiana is not separately sized in public filings. A proposed ~$2.5 billion acquisition by Elevance Health was abandoned in May 2024 after a 15-month regulatory review.
Operations: HMO Louisiana issues the parent's HMO and point-of-service product lines, including Blue Point of Service (POS), Blue Connect, Community Blue, Precision Blue, Signature Blue, and BlueHPN, plus short-term "Bridge Blue" variants. It is also the issuing entity for the Blue Advantage Medicare Advantage HMO and HMO-POS plans. It is an operating insurer, not a patent-holding shell: it owns no asserted patent portfolio of its own.
Litigation posture: The case data show one tracked matter, as plaintiff and never as defendant, which is consistent with an operating company rather than an NPE. The single appearance is not a patent-infringement suit; it is a plaintiff-side antitrust action brought by a health plan seeking damages for alleged overcharges on a branded drug it reimbursed.
Notable case: Louisiana Health Service & Indemnity Co. (BCBS LA) et al. v. Celgene Corp. et al., No. 1:23-cv-07871 (S.D.N.Y., filed Sept. 5, 2023). HMO Louisiana, Inc. is a named co-plaintiff alongside its parent, an individual, and the New York Hotel Trades Council health fund. Plaintiffs alleged Celgene and Bristol Myers Squibb monopolized the market for pomalidomide (Pomalyst) through Walker Process fraud, sham patent litigation, and delayed generic-entry settlements. The court granted defendants' motions to dismiss on March 31, 2025, then granted leave to amend. The venue is the Southern District of New York, not a plaintiff-friendly patent venue such as the Eastern District of Texas.